

## ORGANIZING COMMITTEE

Giovanni Mauri, Milan - IT  
Luca Maria Sconfienza, Milan - IT  
Luigi Solbiati, Milan - IT

## SCIENTIFIC COMMITTEE

Stella Bernardi, Trieste - IT  
Vito Cantisani, Rome - IT  
Jose Luis del Cura, Donostia, Gipuzkoa - ES  
Edouard Ghanassia, Paris - FR  
Laszlo Hegedus, Odense - DK  
Giovanni Mauri, Milan - IT

Hervè Monpeyssen, Paris - FR  
Enrico Papini, Albano Laziale, RM - IT  
Luca Maria Sconfienza, Milan - IT  
Luigi Solbiati, Milan - IT  
Stefano Spiezia, Napoli - IT

## FACULTY

Salvatore Alborino, Macerata - IT  
Camillo Aliberti, Verona - IT  
Filipa Alves de Sousa, Lisbon - PT  
Daniele Barbaro, Livorno - IT  
Stella Bernardi, Trieste - IT  
Vito Cantisani, Rome - IT  
Gianpaolo Carrafiello, Milan - IT  
Andrea Casaril, Verona - IT  
Roberto Luigi Cazzato, Strasbourg - FR  
Eduardo Crespo Vallejo, Madrid - ES  
Pál Ákos Deák, Budapest - HU  
Maurilio Deandrea, Torino - IT  
Jose Luis del Cura, Donostia-San Sebastián - ES  
Harald Dobnig, Graz - AT  
Andrea Frasoldati, Reggio Emilia - IT  
Laura Fugazzola, Milan - IT  
Giovanni Gambelunghe, Perugia - IT  
Edouard Ghanassia, Paris - FR  
Myrsini Gkeli, Athens - GR

Laszlo Hegedus, Odense - DK  
Ozgur Kilickesmez, Istanbul - TR  
Giovanni Mauri, Milan - IT  
Hervè Monpeyssen, Paris - FR  
Roberto Negro, Lecce - IT  
Franco Orsi, Milan - IT  
Giampaolo Papi, Modena - IT  
Enrico Papini, Albano Laziale, RM - IT  
Luca Persani, Milan - IT  
Luca Maria Sconfienza, Milan - IT  
Luigi Solbiati, Milan - IT  
Stefano Spiezia, Naples - IT  
Fulvio Stacul, Trieste - IT  
Pablo Vidal Rios, La Coruña - ES  
Gulsah Yildirim, Istanbul - TR  
Chiara Zini, Florence - IT

MINIMALLY-INVASIVE TREATMENTS  
of the  
**THYROID**  
2023  
State of Art in Europe

MINIMALLY-INVASIVE TREATMENTS  
of the  
**THYROID**  
2023  
State of Art in Europe

## CONFERENCE VENUE

Aula Magna  
University of Milan  
Via Festa del Perdono 7 - 20122 Milan, Italy

## PROVIDER AND ORGANIZING SECRETARIAT

Arseducandi Srl



Viale Gian Galeazzo, 3 | 20136 Milan, Italy  
Tel. +39 02 58189248  
info@arseducandi.it www.arseducandi.it

## OFFICIAL LANGUAGE

English

## CME CREDITS

- An application has been made to the UEMS EACCME\* for CME accreditation of this event.
- The Conference has been accredited at the Italian Continuing Medical Education (CME).

The conference has been granted for nr. 5,6 Italian CME credits for **Physician**: Endocrinology, Oncology, Radiodiagnosis, Internal Medicine, General Surgery, Pathological Anatomy, Otolaryngology, Nuclear Medicine.

## EDUCATIONAL OBJECTIVE:

Guidelines, procedures and clinical documentation

## REGISTRATION - FREE OF CHARGE

The conference is reserved for n. 200 Physicians.

**Dead line registration:** February 6<sup>th</sup>, 2023

Registration includes:

CME Accreditation; Access to all Scientific Sessions; Attendance certificate

Subscribe to the Conference:

[www.termoablazonetiroide.it](http://www.termoablazonetiroide.it)



Milan, Italy

16-17 February 2023

University of Milan - Aula Magna -

MINIMALLY-INVASIVE TREATMENTS

of the  
**THYROID**  
2023

State of Art in Europe

PROVIDER AND ORGANIZING SECRETARIAT



Milan, Italy  
16-17 February 2023  
University of Milan - Aula Magna -

Thursday, 16<sup>th</sup> February, 2023

Friday, 17<sup>th</sup> February, 2023



Minimally Invasive Thyroid Treatments (MITT) have been demonstrated to be an effective treatment for benign and malignant thyroid nodules, and are increasingly applied in the clinical practice all over Europe.

The MITT group has been founded in 2018 in Italy to promote multidisciplinary partnership among physicians with different expertise who share the interest in MITT and to improve the clinical, diagnostic, and therapeutic management of benign and malignant thyroid and parathyroid glands diseases.

During the meeting “Minimally Invasive Thyroid Treatments: 2023 state of the Art in Europe”, expert from all over Europe will share their experience in the application of MITT in patients with benign and malignant thyroid lesions. Present guidelines on the topic will be illustrated, and the state of MITT in the different European countries will be presented.

Furthermore, the present status of the application of different available techniques will be presented, with a special focus on new developments and future perspectives attended for each technique.

On the second day of the meeting, some “hot topics” will be discussed, including the problem of regrowth for benign thyroid nodules, the application of advanced imaging modalities to improve the clinical results, and some critical clinical scenarios like the treatment of microcarcinomas, nodal metastases and parathyroid adenomas.

Before concluding the meeting, a series of real-life clinical cases will be presented and discussed between the expert panel and the participants.

12.30-13.20 Registration  
13.20-13.30 Opening Ceremony

### SESSION I

#### THYROID NODULE MANAGEMENT: WHERE ARE WE?

Chairs: Giampaolo Carrafiello (Milan - IT), Luigi Roberto Cazzato (Strasbourg - FR), Luca Maria Sconfienza (Milan - IT)

13.30-13.50 Thyroid nodules in Europe in 2023: Epidemiology and management - Laszlo Hegedus (Odense - DK)  
13.50-14.10 European guidelines on MITT in benign thyroid nodules - Enrico Papini (Albano Laziale - IT)  
14.10-14.30 European guidelines on MITT in malignant thyroid lesions - Giovanni Mauri (Milan - IT)  
14.30-14.35 Discussion

### SESSION II

#### MITT IN EUROPEAN COUNTRIES

Chairs: Myrsini Gkeli (Athens - GR), Luca Persani (Milan - IT), Luigi Solbiati (Milan - IT)

14.35-14.45 MITT in Italy - Stella Bernardi (Trieste - IT)  
14.45-14.55 MITT in France - Edouard Ghanassia (Paris - FR)  
14.55-15.05 MITT in Austria - Harald Dobnig (Graz - AT)  
15.05-15.15 MITT in Turkey - Gulsah Yildirim (Istanbul - TR)  
15.15-15.25 MITT in Spain - Eduardo Crespo Vallejo (Madrid - ES)  
15.25-15.35 MITT in UK - tbd  
15.35-15.45 MITT in Portugal - Filipa Alves de Sousa (Lisbon - PT)  
15.45-16.00 Panel discussion  
How to expand application of MITT in Europe?

16.00-16.30 Break

### SESSION III

#### MITT TECHNIQUES

Chairs: Jose Luis del Cura (Donostia, Gipuzkoa - ES), Laura Fugazzola (Milan - IT), Franco Orsi (Milan - IT)

16.30-16.45 RFA in 2023 in Europe: where are we now - Fulvio Stacul (Trieste - IT)  
16.45-17.00 RFA: new development and future perspectives - Pal Akos Deak (Budapest - HU)  
17.00-17.15 Laser ablation in 2023: where are we now - Giovanni Gambelunghe (Perugia - IT)  
17.15-17.30 Laser ablation: new development and future perspectives - Pablo Vidal Rios (La Coruña - ES)  
17.30-17.45 MWA in 2023 in Europe: where are we now - Ozgur Kilickesmez (Istanbul - TR)  
17.45-18.00 MWA: new development and future perspectives  
Camillo Aliberti (Verona - IT), Andrea Casaril (Verona - IT)  
18.00-18.15 Improving ablation results: the role CEUS - Maurizio Deandrea (Torino - IT)  
18.15-18.30 Laser, RFA, and MWA: how may I do the choice? - Stefano Spiezia (Naples - IT)  
18.30-19.00 Discussion  
Discussant: Daniele Barbaro (Livorno - IT)

08.30-09.00 Registration

### SESSION IV

#### HOT TOPIC IN MITT

Chairs: Vito Cantisani (Rome - IT), Laszlo Hegedus (Odense - DK), Chiara Zini (Florence - IT)

09.00-09.15 The problem of regrowth in BTN - Roberto Negro (Lecce - IT)  
09.15-09.30 MITT in the management of hyperfunctioning nodule - Salvatore Alborino (Macerata - IT)  
09.30-09.45 MITT in PTMC: new data and future perspectives - Giovanni Mauri (Milano - IT)  
09.45-10.00 Lymph node ablation: where are we now? - Andrea Frasoldati (Reggio Emilia - IT)  
10.00-10.15 Parathyroid ablation, which are the evidences? - Edouard Ghanassia (Paris - FR)  
10.15-10.30 Economical impact of MITT - Giampaolo Papi (Modena - IT)  
10.30-10.45 HIFU in 2023 in Europe: where are we now - Monpeyssen Hervé (Paris - FR)  
10.45-11.00 Panel discussion

11.00-11.30 Break

11.30-12.30 Conclusions and future perspectives  
Stella Bernardi (Trieste - IT), Giovanni Mauri (Milan - IT)

12.30-13.30 **BREAKTHROUGHS IN TECHNOLOGY**

(Session not CME accredited)

Discussant:

Edouard Ghanassia (Paris - FR), Luigi Solbiati (Milan - IT)

Endorsement requested

(to be confirmed)

CIRSE | ETA | SIUMB | SIRM | AME | SIE | ESE | SFE | SFR | AIT | AFTHY

MINIMALLY-INVASIVE TREATMENTS  
of the  
**THYROID** 2023  
State of Art in Europe